Morphotek lands $40M VC round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Morphotek
|
$40M
|
Investor Growth Capital of New York |
Morphotek's lead antibody, MORAb-003, specifically targets the folate receptor alpha, a cell surface receptor over-expressed on ovarian, breast, colorectal, lung and renal tumors. |
|
MTM Laboratories
|
$27.5M
|
HBM BioCapital |
Much of that money will go to the development and commercialization of its diagnostic and screening devices for cervical cancer. |
|
Achaogen
|
$26M
|
Domain Associates |
The company will use the money to advance its lead antibacterial program through clinical proof of concept, and to progress additional programs through preclinical development. |
|
EnVivo Pharmaceuticals
|
$24M
|
Fidelity Biosciences |
EnVivo's first program to enter clinical development later this year is an alpha-7 nicotinic receptor agonist for cognition enhancement in Alzheimer's disease and schizophrenia. |
|
Amyris Biotechnologies
|
$20M
|
Khosla Ventures |
Amyris is using synthetic biology techniques to develop rare chemicals for use in pharmaceuticals and energy. |
|
Santhera Pharmaceuticals
|
$12.5M
|
NGN Capital |
Santhera has a Phase IIb trial underway for JP-1730/fipamezole with Juvantia for Dyskenesia in Parkinson's. |
|
CoDa Therapeutics
|
$10M
|
Domain Associates |
CoDa says it expects to add $5 million to $10 million more to that amount in the next 90 days. Much of that money will go to completing clinical trials. |
|
AGI Dermatics
|
$5.5M
|
Trevi Health Ventures |
AGI is developing skin cancer prevention therapies along with skin care products. |
|
Prolacta Bioscience
|
$5M
|
Arcturus Capital, DFJ Mercury, Philip Capital, Funk Ventures Capital, and the Gideon Hixon Fund |
Prolacta specializes in the nutritional needs of underweight, premature, and critically ill babies. |